Macromoltek (yc W18)
Raised seed funding from Y Combinator, Data Collective VC, Neotribe Ventures, etc. 300+ antibodies engineered & tested. $350k in revenue to date; $450M in the pipeline. Success story includes novel cancer therapeutic designed in <2 weeks, now in pre-clinical trials. Our software-enabled platform reduces traditional process by up to 6x.
- Min investment
- Days Left
- Security Type
Equity is a stock or any other security representing a direct ownership interest.
- April 06, 2021
- July 05, 2021
- Valuation Cap
- Deal Structure
CrowdLustro Research Report
Cofounder & CEO
PhD in Chemical Engineering from Johns Hopkins University. Over 15 years Computational Biology leadership. Lead developer of Rosetta Modeling. Austin Founder of the Year. Reviewer for NSF Small Business grants.
Co-founder & CTO
M.SC. Chemical Engineering. Over 20 years in systems development. Developed PageRank for Fintech industry.
Head of Business Development
Seasoned business development executive, with 20+ years of extensive experience in both the UK and the US. He is passionate about data and computational technologies.
No reports have been submittedBecome a Reporter